Lazar Dimitrov
Directeur/Membre du Conseil chez Lumos Pharma Sub, Inc.
Profil
Dr. Lazar Dimitrov is a Principal at Clarus Ventures LLC.
She received her undergraduate degree from Dartmouth College and a graduate degree from the University of Washington.
Postes actifs de Lazar Dimitrov
| Sociétés | Poste | Début |
|---|---|---|
Lumos Pharma Sub, Inc.
 Lumos Pharma Sub, Inc. Medical/Nursing ServicesHealth Services Lumos Pharma Sub, Inc. develops and commercializes a novel treatment for the rare disease creatine transporter deficiency. It focuses on bringing novel therapies to patients afflicted with unmet medical needs in severe, rare, and genetic diseases. The firm's technology LUM-001 is a repurposed small molecule that is a kinetically similar analog of creatine and has shown promising therapeutic potential for the treatment of creatine transporter deficiency. Lumos Pharma was founded by Richard J. Hawkins in 2010 and is headquartered in Austin, TX. | Directeur/Membre du Conseil | - |
Anciens postes connus de Lazar Dimitrov
| Sociétés | Poste | Fin |
|---|---|---|
Clarus Ventures LLC
 Clarus Ventures LLC Investment ManagersFinance Clarus Ventures LLC (Clarus Ventures) is a venture capital subsidiary of Blackstone, Inc. founded in 2005 by Nicholas G. Galakatos. The firm is headquartered in Cambridge, Massachusetts. | Analyste en capital-investissement | - |
Formation de Lazar Dimitrov
| Dartmouth College | Undergraduate Degree |
| University of Washington | Graduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 2 |
|---|---|
Clarus Ventures LLC
Clarus Ventures LLC Investment ManagersFinance Clarus Ventures LLC (Clarus Ventures) is a venture capital subsidiary of Blackstone, Inc. founded in 2005 by Nicholas G. Galakatos. The firm is headquartered in Cambridge, Massachusetts. | Finance |
Lumos Pharma Sub, Inc.
Lumos Pharma Sub, Inc. Medical/Nursing ServicesHealth Services Lumos Pharma Sub, Inc. develops and commercializes a novel treatment for the rare disease creatine transporter deficiency. It focuses on bringing novel therapies to patients afflicted with unmet medical needs in severe, rare, and genetic diseases. The firm's technology LUM-001 is a repurposed small molecule that is a kinetically similar analog of creatine and has shown promising therapeutic potential for the treatment of creatine transporter deficiency. Lumos Pharma was founded by Richard J. Hawkins in 2010 and is headquartered in Austin, TX. | Health Services |